News

InSphero Partners with Chayon to Bring Advanced 3D In Vitro Technologies to South Korean Researchers

Zurich, Switzerland – November 4, 2024 InSphero, the pioneer in 3D cell culture and organ-on-chip technologies, today announced its distribution partnership with Chayon, a leading Seoul-based laboratory supplies provider. This partnership will bring InSphero’s reliable and scalable 3D in vitro solutions for drug development to South Korean researchers, further expanding the company’s global...

read more

Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer

Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that Frits van Alphen, MD has been appointed as Chief Development Officer (CDO). He succeeds Dr. Gerald P. Parzmair, who stepped...

read more

Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients

Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus (“BKV”)-neutralizing antibody, potravitug. With...

read more

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...

read more

Topadur Pharma AG announces CEO change

The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO to pursue new professional challenges. Since taking on the role in 2023, Mr. Brenneisen has made significant progress in guiding the company toward a future-oriented strategy and fostering a cultural change in preparation...

read more